The state of vessel endothelium in patients with risk factors and ischemic heart disease

10 June 2011
Written by Nevzorova V.A., Shumatov V.B., Nastradin O.V., Zakharchuk N.V.

  UDK: 616.12‑005.4:611.018.74 | Pages: 37-44 | Read full textDownload PDF 


The authors consider vessel endothelium as active en‑ docrine organ that synthesises substances known to be very important for controlling blood clotting, regulation of vasomor tone and arterial tension, filtration function of kidneys, contractive activity of heart, and metabolic support of brain. The paper provides data from literature and authors’ studies on endothelium dysfunction in patients with risk factors for cardiovascular diseases and in patients suffering from ischemic heart disease and arterial hypertension. As reported, given the risk factors, there is a decrease in nitric oxide production and increase in vasopressor endothelium‑1 production. In case of ischemic heart disease the extent of endothelial dysfunction is aggravated and characterised by decreasing endothelium‑dependent vasodilatation. The cerebral blood flow seems to be most protected: considerable changes in the average velocities of blood movement and peripheral vascular resistance indices are observed, given the grade III arterial hypertension.

Links to authors:

V.A. Nevzorova, V.B. Shumatov, O.V. Nastradin, N.V. Zakharchuk
Vladivostok State Medical University (2 Ostryakova Av. Vladivostok 690950 Russia)

  1. Barkagan Z.S., Momot A.P. Diagnosis and controlled treatment of hemostatic disorders. M.: Njudiamed, 2001. 285 p.
  2. Belenkov Ju.N., Mareev V.Ju., Ageev F.T. Endothelial dysfunction in heart failure: the possibility of inhibitor therapy for angiotensin converting enzyme, Kardiologija. 2001. No. 5. P. 100–104.
  3. Brazhnik V.A., Zatejwikov D.A., Sidorenko B.A. The hereditary factors and left ventricular hypertrophy, Kardiologija. 2003. No. 1. P. 78–90.
  4. Buvalcev V.I. Endothelial dysfunction as a new concept of prevention and treatment of cardiovascular diseases, Mezhdunar. med. zhurn. 2001. No.3. P. 202–209.
  5. Burduli N.M., Aleksandrova O.M. The role of endothelial dysfunction under development of microcirculatory disorders in patients with hypertension, Med. vestnik Severnogo Kavkaza. 2007. No. 4 (8). P. 22–26.
  6. Gomazkov O.A. Endothelin in cardiology: molecular, physiological and pathological aspects (review), Kardiologija. 2001. No. 2. P. 50–58.
  7. Zatejwikov D.A., Manushkina L.O., Kudrjashova O.Ju. et al. The endothelial function in patients with hypertension and coronary heart disease, Kardiologija. 2001. No. 6. P. 14–17.
  8. Kocjuba A.E., Babich E.V., Chertok V.M. Vasomotor innervation of the human brain soft shell arteries with different diameters under hypertension, Zhurnal nevropatol. i psihiatrii. 2009. No. 9. P. 56–62.
  9. Kurbanov R.D., Eliseeva M.R., Tursunov R.R. et al. The humoral markers of endothelial dysfunction under essential hypertension,
    Kardiologija. 2003. No. 7. P. 61–64.
  10. Kucherenko N.V., Nastradin O.V., Eliseeva E.V. et al. The vascular endothelium in patients with hypertension in treatment options, Kardiovaskuljarnaja terapija i profilaktika. 2008. No. 1. P. 29–32.
  11. Lutaj M.I., Slobodskoj V.A. Endothelial dysfunction in coronary artery disease: implications and possible correction. The endothelium ‑ a universal regulator of the cardiovascular system,
    Ukr. kardіol. zhurn. 2001. No. 4. P. 79–83.
  12. Malaja L.T., Korzh A.N., Balkovaja L.B. Endothelial dysfunction in the pathology of cardiovascular system. Harkov: Torsing, 2000. 432 p.
  13. Motavkin P.A. What and how innervated in brain? Morfologija. 2007. No. 1. P. 82–84.
  14. Motavkin P.A, Pigolkin Ju.I., Kaminskij Ju.V. Histophysiology circulation in the spinal cord. M.: Nauka, 1994. 232 p.
  15. Motavkin P.A., Pigolkin Ju.I., Lomakin AV., Chertok V.M. The receptor glomeruli and their ultrastructural organization in the arteries of the human pia mater, Arhiv anat., gistol. i jembriol.
    1989. No. 9. P. 14–19.
  16. Motavkin P.A., Chertok V.M. The histophysiology vascular mechanisms of cerebral circulation. M.: Medicina, 1980. 132 p.
  17. Motavkin P.A, Chertok V.M. The brain innervation, Pacific Medical Journal. 2008. No.. 3. P. 11–23.
  18. Nevzorova V.A., Zaharchuk N.V., Plotnikova I.V. The status of cerebral blood flow under hypertensive crises and their possible correction, Kardiologija. 2007. No. 12. P. 20–23.
  19. Nevzorova V.A., Pomogalova O.G., Nastradin O.V. The role of endothelial dysfunction in the progression of the metabolic syndrome from the risk factors to vascular accidents, Pacific Medical
    Journal. 2008. No. 3. P. 69–74.
  20. Rabinovich R.M. The analysis of factors affecting the condition of the blood flow in the internal carotid artery basin under the hypertension, Ter. arhiv. 2008. No. 9. P. 17–20.
  21. Sidorenko B.A., Zatejwikov D.A., Minushkina L.O. Homeostasis and regulation of vascular tone in patients with coronary atherosclerosis and risk factors of its development, Kremlevskaja
    medicina. 2004. No. 4. P. 26–31.
  22. Storozhenko S.Ju., Afanasev Ju.I. State of peripheral vascular resistance, cerebral hemodynamics and cerebrovascular reactivity in patients with hypertension, Ros. med. zhurnal. 2009. No.
    3. P. 9–13.
  23. Suslina Z.A., Geraskina L.A., Fonjakin A.V. The hypertension, brain vascular disease and antihypertensive treatment. M.: Mediagrafiks, 2006. 200 p.
  24. Jeshpulatov A.B., Bozorov H.A., Golovin D.A. et al. The ultrasound assessment of cerebral blood flow in arterial hypertension and its combination with diabetes mellitus type 2, Ultrazvukovaja
    i funkcionalnaja diagnostika. 2009. No. 6. P. 53–55.
  25. Cabrera С., Bohr D. The role of nitric oxide in the central control of blood pressure, Biochem. Biophys. Res. Commun. 2003. Vol.
    206, No. 6. Р. 77–81.
  26. Celermajer D.S., Sorensen K.E., Bull C. et al.Endothelium – dependent dilatation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction, J.
    Am. Cool. Cardiol. 2004. Vol. 24, No. 2. P. 1468–1474.
  27. Celermajer D.S., Sorensen K.E., Gooch V.M. et al. Non‑invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis, Lancet. 1992. Vol. 340, No. 5. Р. 1111–1115.
  28. Charbit M., Blazy I., Gogusev J. el al. Nitric oxide and the reninangiotensin system: contributions to blood pressure in the young rat, Pediatr. Nephrology. 1997. Vol.11, No. 4. P. 617–622.
  29. Clroux J. Endothelium: a new target for cardiovascular therapeutics, J. Am. Col. Cardiol. 2000. Vol. 1. Р. 67–70.
  30. Dernellis J., Panaretou M. Aortic stiffness is an independent predictor of progression to hypertension in nonhypertensive subjects, Hypertension. 2005. Vol. 45, No. 3. P. 426–431.
  31. Hashimoto M., Akishita M., Eto M. et al. Modulation of tndothelium – dependent flow – mediated dilatation of brachial artery by sex and menstrual cycle, Circulation. 1995. Vol. 92, No. 11. P. 3431–3435.
  32. Levin E.R. Endothelins, New Engl. J. Med. 1999. Vol. 333, No. 6. P. 356–363.
  33. Luscher T.F., Barton M. Biology of the endothelium, Clin. Cardiology. 1997. Vol.10 (suppl. 2). P. 3‑10.
  34. Luscher T.F., Barton M. Endothelins and endothelin receptor antagonists, Circulation. 2000. Vol. 102. Р. 2434–2439.
  35. O’Donnell V.B., Freeman B.A. Interactions between nitric oxide and lipid oxidation pathways: implications for vascular disease, Circ. Res. 2001. Vol. 88, No. 1. Р. 12–21.
  36. Palmieri G.M. The endothelium in health and in cardiovascular disease, Health Sci. J. 1997. Vol. 16, No. 2. P. 136–141.
  37. Rongen G.A., Smits P., Thien T. Endothelium and the regulation of vascular tone with emphasis on the role of nitric oxide: рhysiology, pathophysiology and clinical implications, Neth. J. Med. 2000. Vol. 44, No. 4. P. 26–35.
  38. Schiffrin E.L., Touyz R.M. Vascular biology of endothelin, J. Cordiovasc. Pharmacol. 1998. Vol. 3, No. 3. P. 2–13.
  39. Taddei S., Virdis A., Ghiadoni L. et al. Endothelial dysfunction in hypertension, J. Cardiovasc. Pharmacol. 2001. Vol. 13. Р. 205–210.
  40. Vanhoutte P.M., Mombouli J.V. Vascular endothelium: vasoactive mediators, Prog. Cardiovase. Dis. 1996. Vol. 39, No. 2. Р. 229–238.
  41. Weber C., Schmitt R., Birnboeck H. et al. Pharmacokinetics and pharmacodynamics of the endothelin‑receptor antagonist bosentan in healthy human subjects, Clin. Pharm. Ther. 1996. Vol. 60. P. 124–137.


Founded in 1997  |  Editions in a year: 4, Articles in one issue: 30 |  ISSN of print version: 1609-1175  |  Ind.: 18410 (Agency "Rospechat’")  |  Edition: 1000 c.